Biopharmas raising money in public or private financings, including: Azitra, Cel-Sci, Cogent, Engene, Evoke, Immunome, Larimar, Metagenomi, Newamsterdam, Nextpoint, Telomir.

Biopharmas raising money in public or private financings, including: Areteia, Bioxcel, Crispr, Curasight, Ensysce, Kyverna, Profoundbio, Sana, Shuttle, Sudo, Sunshine.

Medicxi is spinning six of its early stage companies into an immuno-dermatology specialist and turbocharging development with a $100 million seed round.

Biopharmas raising money in public or private financings, including: Lineage.

Gene editing firm Metagenomi Inc. priced an IPO raising $93.8 million, while Telomir Pharmaceuticals Inc., a company developing small-molecule therapies targeting inflammatory disease, priced a more modest $7 million IPO. While they mark the second and third biopharma IPOs to price this week, and the sixth and seventh for 2024, the two aptly named companies are the first preclinical-stage ventures to test the public markets this year.

Biopharmas raising money in public or private financings, including: Alligator, Bioxcel, Cel-Sci, Evoke, Helix Acquisition, Immix, Lineage Cell, Sensorion, Tenax, Tenaya, TME, YM.

Biopharmas raising money in public or private financings, including: Kyverna, Kyverna, Neurona, Sana.

Biopharmas raising money in public or private financings, including: 4D Molecular, Alto, Attralus, Biorestorative, Cingulate, Clearside, Evaxion, Immix, Jasper, Neximmune, Pepgen, Scion, Vaccinex, Xinnate.

Biopharmas raising money in public or private financings, including: Kyverna, Lineage Cell, Neonc, Revelation, Theralase.